SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr. Reddy's Laboratories trades higher on the bourses

19 Dec 2014 Evaluate

Dr. Reddys Laboratories is currently trading at Rs. 3198.00, up by 47.50 points or 1.51% from its previous closing of Rs. 3150.50 on the BSE.

The scrip opened at Rs. 3178.50 and has touched a high and low of Rs. 3200.00 and Rs. 3171.00 respectively. So far 5528 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 3662.00 on 01-Dec-2014 and a 52 week low of Rs. 2250.00 on 19-May-2014.

Last one week high and low of the scrip stood at Rs. 3427.60 and Rs. 3060.00 respectively. The current market cap of the company is Rs. 54218.93 crore.

The promoters holding in the company stood at 25.49% while Institutions and Non-Institutions held 43.79% and 13.69% respectively.

Dr. Reddy's Laboratories has closed the acquisition of Habitrol brand (an over-the-counter nicotine replacement therapy transdermal patch) from Novartis Consumer Health Inc following issuance of the proposed consent order from the U.S. Federal Trade Commission (FTC) on November 26, 2014. The company had earlier entered into an asset purchase agreement with Novartis Consumer Health Inc to acquire the title and rights of Habitrol brand and to market the product in the U.S. market. With this closure, the company has assumed responsibility for the product and will commence shipments of the product in the market shortly.

Dr. Reddy’s is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.

 

Dr. Reddys Lab Share Price

1220.75 -11.50 (-0.93%)
21-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.25
Dr. Reddys Lab 1220.75
Cipla 1232.90
Zydus Lifesciences 928.85
Lupin 2311.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×